Emergex
  • About Us
      • Team
      • Board of Directors
      • Special Advisors
  • Technology
      • Advantages of Emergex’s Vaccines
      • Set-point Vaccines
  • Pipeline
  • Media Centre
      • Press Releases
      • In the News
      • White Papers
  • Contact Us
  • Menu Menu
You are here: Home1 / Pipeline

We have a growing pipeline of vaccine candidates.

Lead programme: Flavivirus for Dengue Fever

Our most advanced development programme is a Flavivirus vaccine candidate primarily against Dengue Fever (DV1-DV4), which may also deliver responses against other Flaviviruses such as the Zika and Yellow Fever viruses.

This programme has successfully completed preclinical testing. Phase I and subsequent clinical trials are planned to start in Switzerland, Singapore and Brazil.

Development programmes

We also have programmes in development for a universal Influenza (flu) vaccine, a universal Filovirus vaccine (to target viruses including Ebola and Marburg), a Yellow Fever Booster vaccine, and a Chikungunya virus vaccine.

We are also working on vaccines for several intracellular bacterial infections, such as Francisella tularensis, currently categorized as a Tier 1 biothreat priority by the US government.

Partnered programmes

We have partnered with the IMCB of Singapore to develop a vaccine for the emerging threat of Hand, Foot and Mouth (HFM) disease.

© EMERGEX VACCINES

Website maintained by Digital Trading

  • Contact Us
LinkedIn
Scroll to top